Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 28:620:217692.
doi: 10.1016/j.canlet.2025.217692. Epub 2025 Apr 3.

TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells

Affiliations

TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells

Manjari Kundu et al. Cancer Lett. .

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential cancer therapeutic that induces apoptosis in cancer cells while sparing the non-malignant cells in preclinical models. However, its efficacy in clinical trials has been limited, suggesting unknown mechanisms modulating TRAIL activity in patients. We hypothesized that TRAIL treatment elicits transcriptional changes in triple negative breast cancer (TNBC) cells that alter the immune milieu. RNAseq analysis of MDA-MB-231 cells along with validation in additional cell lines demonstrated that TRAIL induced cytokines such as CXCLs 1, 2, 3, 8,11 and IL-6, which are known to modify neutrophil function. Mechanistically, TRAIL dependent induction of the cytokines was predominantly mediated by death receptor 5, caspase-8 and the non-canonical NFKB2 pathway. These cytokines produced by TRAIL-treated TNBC cells enhanced chemotaxis of normal human donor isolated neutrophils. Using TNBC xenograft models, TRAIL induced activation of NFkB2 pathway, cytokine production and increased neutrophil recruitment into the tumors. Moreover, preincubation of neutrophils in supernatants from TRAIL-treated TNBC cells significantly impaired neutrophil function as measured by reduced respiratory burst and cytotoxic effect against TNBC cells. Transcriptomic analysis of neutrophils incubated with either TRAIL alone or supernatant of TRAIL-treated TNBC cells revealed increased expression of inflammatory cytokines, immune modulatory genes, immune checkpoint genes, and genes implicated in delayed neutrophil apoptosis. Functional studies showed that these neutrophils suppress T cell proliferation and augment Treg suppressive phenotype. Collectively, our study demonstrates a novel role of TRAIL-induced NFKB2-dependent cytokine production that promotes neutrophil chemotaxis and neutrophil-mediated immune suppression.

Keywords: Apoptosis; Neutrophil chemoattractant cytokines; Neutrophil-mediated immune suppression; Non-canonical nuclear factor-kappa B signaling; Tumor necrosis factor-related apoptosis-inducing ligand.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Update of

References

    1. Sharma P, Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist, 2016. 21(9): p. 1050–62. - PMC - PubMed
    1. Bardia A, Hurvitz SA, and Rugo HS, Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. N Engl J Med, 2021. 385(3): p. e12. - PubMed
    1. Hattori M, et al., Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355. Cancer Med, 2023. 12(9): p. 10280–10293. - PMC - PubMed
    1. Haiderali A, et al., Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer. Future Oncol, 2024. - PMC - PubMed
    1. Schmid P, et al., Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med, 2022. 386(6): p. 556–567. - PubMed

MeSH terms

LinkOut - more resources